Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 September 2022 | Story Jóhann Thormählen | Photo iStock
Cervical cancer awareness ribbon
Cervical Cancer Awareness Month is observed in September in South Africa to encourage women to go for screening to prevent it.

Cervical cancer is the second most common cancer among women in South Africa, and many die from it each year – but it can be prevented.

According to Dr Arina Meyer, medical practitioner in Kovsie Health at the University of the Free State, this is one of the reasons why it is important to be informed, take precautions, and raise awareness about the disease.

Cervical Cancer Awareness Month is observed in September in South Africa with the aim of encouraging women to go for screening to prevent it.

Although medical statistics paint a bleak picture, Meyer says there is hope. “It is important to know that cervical cancer can be prevented. And when it is diagnosed early, it can be treated.”

Statistics and causes

According to her, figures show the occurrence of cervical cancer to be between 22,8 and 27 per 100 000 women in South Africa. 

“More than 5 700 new cases are reported each year, as well as more than 3 000 deaths. Cervical cancer is the second most common cancer – after skin cancer – in South Africa.”

Meyer says when one look at these numbers, it is important to commemorate Cervical Cancer Awareness Month, as women need to be informed about their annual check-up, possible symptoms, and signs of the cancer.

Most cervical cancers are caused by the human papillomavirus (HPV), which is transmitted through sexual contact. Therefore, the HPV is seen as a sexually transmitted disease.

“There are different types of HPV. Some cause cervical cancer and other genital warts. One can develop one or both conditions, depending on the type of virus you have,” says Meyer.

Prevention and reducing the risk

According to her, preventative action is the best method. Going for a cervical screening every year when you become sexually active, such as a Pap smear or Pap test, will help in the early detection and removal of abnormal cells.

There is also a vaccine for protection against HPV, which is available from the age of nine. Meyer says there are two vaccines in South Africa.

“By getting the vaccine early, before any sexual activity, the spread of HPV – and therefore cervical cancer – can be prevented. Up to 90% of cancers can be prevented.
“Unfortunately, if someone has already been infected by the HPV, it cannot be treated by the vaccine.”

The UFS medical practitioner says the best ways to reduce the risk of cervical cancer are to go for an annual Pap smear, a follow-up after an abnormal test result, the vaccine, safe sex, and to stop smoking.

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept